FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance ...

Managing raw material variation and process risks is critical to ensuring a high level of quality and consistency in drug development and manufacturing. Supply chain partners across the industry must ...

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...

Most emerging life sciences companies already understand the importance of thinking about the future patient. Leadership teams routinely model future treatment pathways, reimbursement environments, ...

On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Dr. Ebrahim Delpassand, founder, chairman and CEO at RadioMedix, explains why ...

It supports targeted glycan modulation without compromising cell culture performance or critical quality attributes. Increases galactosylation, shifting glycan profiles from G0F to G1F and G2F.

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” panelists talk about the importance of harmonization across regulatory agencies ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Richard Valeix, CEO at Telix Therapeutics describes the on-demand requirements for ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Richard Valeix, CEO at Telix Therapeutics, talks about the similarities between ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” our panelists talk about the synergies between diagnostics and therapeutics in ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.